Inflammation is an integral part to numerous medical conditions and coincides with nearly all types of injuries and insults to the body. Some studies have reported inflammation in Autism, Stroke, Diabetes, Alzheimer's, Traumatic Brain Injury and many other conditions. Hyperbaric oxygen therapy (HBOT) has been demonstrated to substantially decrease inflammation throughout the body. HBOT drives increased levels of oxygen into the body, which travels through the plasma, subsequently reducing inflammation and pain. Studies have shown that HBOT increases anti-inflammatory levels and provides increased cellular aid to heal target regions. As oxygen serves as one of the primary mechanisms to reduce inflammation, HBOT creates the environment where this process is stimulated and enhanced. Studies have demonstrated the benefits of HBOT for inflammation with the following:

• Support Anti-Inflammatory Process at the Cellular Level: decreases acute/chronic inflammation, minimizes pain & discomfort, reduces inflammatory proteins, promotes anti-inflammatory proteins, reduces swelling, accelerates tissue repair and healing
  

• Reduce Brain Inflammation: reduces severity of Autism symptoms, supports the prevention and treatment of stroke, reduces risk of Alzheimer's and Parkinson's Disease

• Decrease Gastrointestinal Inflammation: remediates inflammatory bowel disease, helps improve ulcerative colitis, improves nutritional absorption

• Relieve Soft Tissue/Joint Inflammation: remediates Arthritis, reduces tendinitis, accelerates recovery from sports-related and high impact injuries

• Prevent the Onset of Chronic Inflammatory-Related Diseases: decreases cancer risk and progression, reduces risk of coronary heart disease heart attack and stroke, improves diabetic conditions linked to inflammation
  

Study: Inflammation & Hardening of the arteries Decreased with HBOT

A study published in July 2008 examined the effects of HBOT on compromised blood flow due to hardening of the arteries with mice. Two groups of mice were treated with either 5 or 10 weeks of HBOT, whereas two other groups remained untreated and used as a control group. After the introduction of increased cholesterol levels, the treated group exhibited positive changes in the immune/inflammatory after HBOT. This study demonstrated that HBOT significantly reduced circulating levels of cholesterol that can cause heart disease, kidney disease and stroke. Additionally, HBOT resulted in a substantial decrease in the production of pro-inflammatory proteins and showed a marked increase in the production of anti-inflammatory proteins. The observed improvements were already noted after only 5 weeks of treatment.